mTOR Signaling Pathway Regulates the Release of Proinflammatory Molecule CCL5 Implicated in the Pathogenesis of Autism Spectrum Disorder

Autism spectrum disorder (ASD) is a complex pervasive neurodevelopmental disorder and neuroinflammation may contribute to the pathogenesis of ASD. However, the exact mechanisms of abnormal release of proinflammatory mediators in ASD remain poorly understood. This study reports elevated plasma levels of the proinflammatory chemokine (C-C motif) ligand 5 (CCL5) in children with ASD, suggesting an aberrant inflammatory response appearing in the development of ASD. Mining of the expression data of brain or blood tissue from individuals with ASD reveals that mTOR signaling is aberrantly activated in ASD patients. Our in vitro study shows that suppression of mTOR reduces the gene expression and release of CCL5 from human microglia, supporting that CCL5 expression is regulated by mTOR activity. Furthermore, bacterial lipopolysaccharide (LPS)-induced CCL5 expression can be counteracted by siRNA against NF-kappa B, suggests a determining role of NF-kappa B in upregulating CCL5 expression. However, a direct regulatory relationship between the NF-kappa B element and the mTOR signaling pathway was not observed in rapamycin-treated cells. Our results show that the phosphorylated CREB can be induced to suppress CCL5 expression by outcompeting NF-kappa B in binding to CREB-binding protein (CREBBP) once the mTOR signaling pathway is inhibited. We propose that the activation of mTOR signaling in ASD may induce the suppression of phosphorylation of CREB, which in turn results in the increased binding of CREBBP to NF-kappa B, a competitor of phosphorylated CREB to drive expression of CCL5. Our study sheds new light on the inflammatory mechanisms of ASD and paves the way for the development of therapeutic strategy for ASD.

Automated summary

This study reports elevated levels of the proinflammatory chemokine CCL5 in children with Autism Spectrum Disorder (ASD), suggesting an abnormal inflammatory response in the development of ASD. The study also reveals that the mTOR signaling pathway is aberrantly activated in ASD patients and that suppression of mTOR reduces the expression of CCL5. Further analysis shows that NF-kappa B plays a determining role in upregulating CCL5 expression, but there is no direct regulatory relationship between NF-kappa B and the mTOR signaling pathway. The study suggests that the activation of mTOR signaling in ASD may induce the suppression of phosphorylation of CREB, leading to increased binding of CREBBP to NF-kappa B and thus driving the expression of CCL5.